ES2369535T3 - Uso de alquilfosfocolinas en combinación con medicamentos antitumorales. - Google Patents
Uso de alquilfosfocolinas en combinación con medicamentos antitumorales. Download PDFInfo
- Publication number
- ES2369535T3 ES2369535T3 ES03766336T ES03766336T ES2369535T3 ES 2369535 T3 ES2369535 T3 ES 2369535T3 ES 03766336 T ES03766336 T ES 03766336T ES 03766336 T ES03766336 T ES 03766336T ES 2369535 T3 ES2369535 T3 ES 2369535T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- amino
- branched
- independently
- straight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 title description 8
- -1 alkyl phosphocholines Chemical class 0.000 claims abstract description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 4
- 230000000340 anti-metabolite Effects 0.000 claims abstract description 3
- 229940100197 antimetabolite Drugs 0.000 claims abstract description 3
- 239000002256 antimetabolite Substances 0.000 claims abstract description 3
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 6
- 201000008275 breast carcinoma Diseases 0.000 description 6
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- 229960005536 Alkyl-lysophospholipid Drugs 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009396 radiation induced apoptosis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39961502P | 2002-07-30 | 2002-07-30 | |
| US399615P | 2002-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2369535T3 true ES2369535T3 (es) | 2011-12-01 |
Family
ID=31495746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03766336T Expired - Lifetime ES2369535T3 (es) | 2002-07-30 | 2003-07-29 | Uso de alquilfosfocolinas en combinación con medicamentos antitumorales. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8389497B2 (enExample) |
| EP (2) | EP1545553B1 (enExample) |
| JP (1) | JP2005535688A (enExample) |
| KR (3) | KR101066804B1 (enExample) |
| CN (1) | CN1302780C (enExample) |
| AR (1) | AR040717A1 (enExample) |
| AT (1) | ATE516036T1 (enExample) |
| AU (2) | AU2003253350B2 (enExample) |
| BR (1) | BR0313048A (enExample) |
| CA (1) | CA2493023C (enExample) |
| CY (1) | CY1111902T1 (enExample) |
| DK (1) | DK1545553T3 (enExample) |
| ES (1) | ES2369535T3 (enExample) |
| HR (1) | HRP20050184B1 (enExample) |
| IL (1) | IL166329A (enExample) |
| MX (1) | MXPA05001203A (enExample) |
| NO (1) | NO335196B1 (enExample) |
| NZ (1) | NZ538428A (enExample) |
| PL (1) | PL375493A1 (enExample) |
| PT (1) | PT1545553E (enExample) |
| RU (1) | RU2005105693A (enExample) |
| SI (1) | SI1545553T1 (enExample) |
| TW (1) | TWI332007B (enExample) |
| UA (1) | UA82322C2 (enExample) |
| WO (1) | WO2004012744A1 (enExample) |
| ZA (1) | ZA200500453B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383605B2 (en) | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| TWI332007B (en) | 2002-07-30 | 2010-10-21 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals |
| DE10324911B4 (de) | 2003-05-30 | 2005-08-18 | Siemens Ag | Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen |
| WO2006081452A2 (en) * | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
| WO2009018233A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
| JP5232009B2 (ja) * | 2005-12-19 | 2013-07-10 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された細胞毒性を有するアルキルリン脂質誘導体並びにそれらの使用 |
| EP1800684A1 (en) * | 2005-12-20 | 2007-06-27 | Zentaris GmbH | Novel alkyl phospholipid derivatives and uses thereof |
| CN101340918B (zh) * | 2005-12-19 | 2012-10-03 | 阿特纳赞塔里斯有限公司 | 具有降低细胞毒性的新烷基磷脂衍生物及其用途 |
| US8703179B2 (en) | 2006-05-11 | 2014-04-22 | Kimberly-Clark Worldwide, Inc. | Mucosal formulation |
| MX2011006167A (es) * | 2008-12-11 | 2011-07-28 | Abraxis Bioscience Llc | Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion. |
| MX2011011596A (es) | 2010-03-31 | 2012-02-01 | Keryx Biopharmaceuticals Inc | Perifosina y capecitabina como un tratamiento combinado para cancer. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59205998D1 (de) * | 1991-07-04 | 1996-05-23 | Asta Medica Ag | Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung |
| US5942639A (en) * | 1991-07-04 | 1999-08-24 | Asta Medica Aktiengesellschaft | Process for the preparation of alkylphosphocholines and the production thereof in pure form |
| US6172050B1 (en) * | 1992-07-11 | 2001-01-09 | Asta Medica Aktiengesellschaft | Phospholipid derivatives |
| JP3079993B2 (ja) * | 1996-03-27 | 2000-08-21 | 日本電気株式会社 | 真空マイクロデバイスおよびその製造方法 |
| DE19650778C2 (de) * | 1996-12-06 | 2001-01-04 | Asta Medica Ag | Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie |
| PL189654B1 (pl) * | 1998-01-22 | 2005-09-30 | Zentaris Gmbh | Zastosowanie miltefosyny do wytwarzania leków |
| PT1135193E (pt) * | 1998-12-04 | 2003-01-31 | Max Delbrueck Centrum | Agentes para o tratamento de tumores a base de lipossomas e compreendendo tamoxifeno |
| CA2356736A1 (en) * | 1998-12-21 | 2000-06-29 | Inkeysa. S.A. | Use of etherlysophospholipids as antiinflammatory agents |
| EP2762140B1 (en) * | 2001-02-19 | 2017-03-22 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
| PL365285A1 (en) * | 2001-03-23 | 2004-12-27 | Shire Biochem Inc. | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
| WO2003005522A1 (es) | 2001-07-04 | 2003-01-16 | Acuna Arturo | Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica. |
| US20060084612A1 (en) * | 2002-01-02 | 2006-04-20 | Geroni Maria C | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| TWI332007B (en) | 2002-07-30 | 2010-10-21 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals |
| WO2005000318A2 (en) * | 2003-06-23 | 2005-01-06 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| WO2006081452A2 (en) | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
| CN101340918B (zh) * | 2005-12-19 | 2012-10-03 | 阿特纳赞塔里斯有限公司 | 具有降低细胞毒性的新烷基磷脂衍生物及其用途 |
| MX2011011596A (es) * | 2010-03-31 | 2012-02-01 | Keryx Biopharmaceuticals Inc | Perifosina y capecitabina como un tratamiento combinado para cancer. |
-
2003
- 2003-07-29 TW TW092120705A patent/TWI332007B/zh not_active IP Right Cessation
- 2003-07-29 ES ES03766336T patent/ES2369535T3/es not_active Expired - Lifetime
- 2003-07-29 EP EP03766336A patent/EP1545553B1/de not_active Expired - Lifetime
- 2003-07-29 NZ NZ538428A patent/NZ538428A/en not_active IP Right Cessation
- 2003-07-29 AT AT03766336T patent/ATE516036T1/de active
- 2003-07-29 AR AR20030102710A patent/AR040717A1/es unknown
- 2003-07-29 MX MXPA05001203A patent/MXPA05001203A/es active IP Right Grant
- 2003-07-29 PT PT03766336T patent/PT1545553E/pt unknown
- 2003-07-29 CN CNB038181010A patent/CN1302780C/zh not_active Expired - Fee Related
- 2003-07-29 AU AU2003253350A patent/AU2003253350B2/en not_active Ceased
- 2003-07-29 RU RU2005105693/15A patent/RU2005105693A/ru unknown
- 2003-07-29 HR HRP20050184AA patent/HRP20050184B1/hr not_active IP Right Cessation
- 2003-07-29 JP JP2004525354A patent/JP2005535688A/ja active Pending
- 2003-07-29 KR KR1020057001510A patent/KR101066804B1/ko not_active Expired - Lifetime
- 2003-07-29 SI SI200332027T patent/SI1545553T1/sl unknown
- 2003-07-29 WO PCT/EP2003/008346 patent/WO2004012744A1/de not_active Ceased
- 2003-07-29 PL PL03375493A patent/PL375493A1/xx unknown
- 2003-07-29 KR KR1020117017914A patent/KR20110102485A/ko not_active Ceased
- 2003-07-29 UA UAA200500510A patent/UA82322C2/uk unknown
- 2003-07-29 DK DK03766336.6T patent/DK1545553T3/da active
- 2003-07-29 CA CA2493023A patent/CA2493023C/en not_active Expired - Lifetime
- 2003-07-29 BR BR0313048-7A patent/BR0313048A/pt not_active IP Right Cessation
- 2003-07-29 KR KR1020127034433A patent/KR20130016413A/ko not_active Ceased
- 2003-07-29 EP EP10010451A patent/EP2301551A1/de not_active Withdrawn
- 2003-07-30 US US10/632,187 patent/US8389497B2/en not_active Expired - Fee Related
-
2005
- 2005-01-17 IL IL166329A patent/IL166329A/en not_active IP Right Cessation
- 2005-01-18 ZA ZA2005/00453A patent/ZA200500453B/en unknown
- 2005-02-25 NO NO20051040A patent/NO335196B1/no not_active IP Right Cessation
-
2008
- 2008-07-10 AU AU2008203060A patent/AU2008203060B2/en not_active Ceased
-
2010
- 2010-03-31 US US12/751,608 patent/US8507710B2/en not_active Expired - Fee Related
- 2010-03-31 US US12/751,454 patent/US8551977B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 CY CY20111100944T patent/CY1111902T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008203060B2 (en) | Use of alkyl phosphocholines in combination with antitumor medicaments | |
| ES2621857T3 (es) | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 | |
| ES2367028T3 (es) | Composiciones sinérgicas con fk-228. | |
| ES2746105T3 (es) | Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer | |
| ES2727686T3 (es) | Tratamiento de enfermedades que implican mucina | |
| US20110028421A1 (en) | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals | |
| ES2743701T3 (es) | Conjugados de ligando-fármaco del receptor sigma-2 como compuestos antitumorales, métodos de síntesis y usos de los mismos | |
| ES2390801T3 (es) | Procedimiento para el tratamiento de la neoplasia con una combinación de agentes quimioterápicos y radiación | |
| ES2184496T3 (es) | Empleo de determinados acidos bifosfonicos y sus derivados para la fabricacion de farmacos para la prevencion y el tratamiento de enfermedades autoinmunes y alergias. | |
| AU2011204918B2 (en) | Use of alkylphosphocholines in combination with antitumor medicaments | |
| ES2396718T3 (es) | Uso de compuestos de glicerol tri-sustituidos para el tratamiento de neoplasias malignas | |
| CA2436332A1 (en) | Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals | |
| WO2011046901A2 (en) | Broad spectrum antiviral and methods of use | |
| PT2404608E (pt) | Derivado de colestanol para utilização combinada |